SanBio
4592.TTSE GROWTHPharmaceutical
Financials · Standalone
| Fiscal year ended | 2026-01 | 2025-01 | 2024-01 | 2023-01 | 2022-01 | 2021-01 |
|---|---|---|---|---|---|---|
| Operating income | −¥1.7bn | −¥1.5bn | −¥1.6bn | −¥1.9bn | −¥1.5bn | — |
| Ordinary income | −¥2.2bn | −¥751m | ¥417m | ¥1.9bn | ¥932m | −¥1.8bn |
| Total assets | ¥15.5bn | ¥3.2bn | ¥4.6bn | ¥6.6bn | ¥4.9bn | ¥12.7bn |
| Net assets / equity | ¥13.6bn | ¥1.7bn | ¥2.7bn | ¥4.4bn | ¥2.0bn | ¥8.4bn |
| EPS (basic) | ¥-46.62 | ¥-51.49 | ¥-63.29 | ¥-153.17 | ¥-124.35 | ¥-57.49 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 14
| Period | Form | Figures |
|---|---|---|
| 2026-02-01 → 2026-07-31 | Half-year | 62 figures · EDINET |
| 2025-02-01 → 2026-01-31 | Annual | 168 figures · EDINET |
| 2025-02-01 → 2025-07-31 | Half-year | 62 figures · EDINET |
| 2024-02-01 → 2025-01-31 | Annual | 168 figures · EDINET |
| 2024-02-01 → 2024-07-31 | Half-year | 62 figures · EDINET |
| 2024-02-01 → 2024-04-30 | Quarterly Q1 | 38 figures · EDINET |
| 2023-02-01 → 2024-01-31 | Annual | 168 figures · EDINET |
| 2023-02-01 → 2023-10-31 | Quarterly Q3 | 40 figures · EDINET |
| 2023-02-01 → 2023-07-31 | Quarterly Q2 | 64 figures · EDINET |
| 2023-02-01 → 2023-04-30 | Quarterly Q1 | 38 figures · EDINET |
| 2022-02-01 → 2023-01-31 | Annual | 168 figures · EDINET |
| 2022-02-01 → 2022-10-31 | Quarterly Q3 | 40 figures · EDINET |
| 2022-02-01 → 2022-07-31 | Quarterly Q2 | 64 figures · EDINET |
| 2022-02-01 → 2022-04-30 | Quarterly Q1 | 38 figures · EDINET |
21 more reports are still being processed.